孟鲁司特联合抗生素治疗支气管扩张症的临床观察

Clinical observation of montelukast combined with antibiotics in the treatment of bronchiectasis

目的观察孟鲁司特联合抗生素治疗支气管扩张症的临床疗效。方法选取支气管扩张症患者60例,随机平均分为研究组和对照组,2个月的疗程中对照组给予常规抗生素及对症支持治疗,研究组在此基础上每日加用孟鲁司特治疗,观察两组的临床疗效差异。结果研究组的咳嗽、咳痰症状较对照组明显减轻,痰培养阳性率低于对照组,半年内住院及咯血次数明显少于对照组,研究组总有效率优于对照组,差异有统计学意义(P<0.05);研究组的肺功能指标(FVC、FEV1、FEV1/FVC%、DLCO%)较对照组稍有改善,差异无统计学意义(P>0.05)。结论孟鲁司特联合抗生素治疗能显著改善支气管扩张患者的临床症状,降低患者的急性加重住院率。

Objective To observe the clinical effect of montelukast combined with antibiotics in the treatment of bronchiectasis. Methods 60 patients with bronchiectasis were randomly divided into the treatment group and the control group on average. The control group was given conventional antibiotics and support therapy, and the treatment group was additionally treated with montelukast. All of them were treated for two months, and their clinical curative effect was observed. Results The symptoms of cough and sputum relived more obviously in the treatment group than in the control group, the positive rate of sputum culture was lower inthe treatment group than in the control group, the times of hospital stay and haemoptysis were significantly less in the treatment group than in the control group, and the total effective rate was better in the treatment group than in the control group （P 〈0. 05 ）. There was no significant difference in lung function indexes （FVC, FEV1 , FEV/FVC% and DLCO% ） between the two groups （ P〉0. 05）. Conclusion Montelukast combined with antibiotic therapy can significantly improve the clinical symptoms and decrease the rate of hospital stay and haemoptysis in the treatment of patients with bronchiectasis.